Antipsychotic Polypharmacy: Prevalence, Background and Consequences
|ClinicalTrials.gov Identifier: NCT00541398|
Recruitment Status : Completed
First Posted : October 10, 2007
Last Update Posted : November 2, 2009
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Behavioral: Implementation of guideline||Not Applicable|
Several surveys have shown a high prevalence of antipsychotic polypharmacy (concomitant prescription of at least 2 different antipsychotics) among patients with schizophrenia even though international guidelines recommend monotherapy.
From register data areas with differences in the prevalence of antipsychotic polypharmacy will be identified. Two high prevalence areas will be randomized to either control or intervention area. In the intervention area an intensive educational intervention consisting of outreach visits with a multifaceted approach will be carried out with the duration of 1 year.
Differences in health staff related factors such as knowledge and attitude towards clinical guidelines will be assessed with a questionnaire before and after the intervention in the intervention area as well as in the low prevalence area at baseline.
Medical records data describing the use of antipsychotic polypharmacy will be collected. With register data health economic issues will be assessed.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||222 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Antipsychotic Polypharmacy: Prevalence, Background and Consequences|
|Study Start Date :||January 2008|
|Actual Primary Completion Date :||January 2009|
|Actual Study Completion Date :||October 2009|
Behavioral: Implementation of guideline
Outreach visits with interactive education for health staff
|No Intervention: B|
- Prevalence of antipsychotic polypharmacy [ Time Frame: 1 year ]
- Questionnaire assessment of non-patient related factors. Medical records data. Cost-effectiveness analysis. [ Time Frame: 1 year ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00541398
|Glostrup, Denmark, 2600|
|Study Director:||Birte Glenthøj, Professor||University of Copenhagen|